Study summary
A bispecific antibody cleared measurable disease in most people with high-risk smoldering myeloma
92%progression-free at 2 years, vs 49% with lenalidomide-dexamethasone
What was tested
Teclistamab, a BCMA-CD3 bispecific antibody approved for myeloma, against lenalidomide-dexamethasone, for high-risk smoldering myeloma.
What they found
- 2-year progression-free survival was 92% vs 49%.
- No measurable residual disease (at 10^-5) in 82.2% of people on teclistamab.
- Cytokine release syndrome was mild; serious infections were similar (20% vs 21%).
What it means
Raises the prospect of a time-limited treatment that may stop myeloma before it starts.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.